Drug development for cancer: implications for chemical modifiers.
Chabner
B A
BA
Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892.
Shoemaker
D
D
D000970:Antineoplastic Agents; D002626:Chemistry, Pharmaceutical; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009316:National Institutes of Health (U.S.); D014481:United States
D000970:Antineoplastic Agents